

# Meningococcal Vaccines – Parent Version



This document lays out the recommended adolescent vaccinations for Meningococcal disease in the United States. Each of these have been approved by the FDA for administration within the United States. Brand names, manufacturers, and recommendations for each vaccination is provided below. NOTE: this document only includes recommended vaccines for adolescents and is not an inclusive list of all of the Meningococcal vaccines available. For an all-inclusive list, see Meningococcal Vaccines – Provider Version.

Vaccine Name and Manufacturer <sup>o</sup>	Serogroups Covered*	Ages and Recommendations	Doses in Series
<b>Routinely Recommended for Adolescence: Quadrivalent Meningococcal Conjugate Vaccine</b>			
<b>Vaccine Name: Menactra</b> <b>Manufactured by:</b> <b>Sanofi Pasteur Inc.</b>	A, C, W, Y	<ul style="list-style-type: none"> <li>11-12 year olds – 1<sup>st</sup> dose of a 2 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The booster (or 2<sup>nd</sup> dose) should be given at 16 years old</li> </ul> </li> <li>13-18 year olds – 1<sup>st</sup> dose (if not previously vaccinated) of a 2 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The booster (or 2<sup>nd</sup> dose) should be given at 16 years old</li> </ul> </li> </ul>	2 dose series for adolescence
<b>Vaccine Name: Menveo</b> <b>Manufactured by:</b> <b>GlaxoSmithKline</b>	A, C, W, Y	<ul style="list-style-type: none"> <li>11-12 year olds - 1<sup>st</sup> dose of a 2 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The booster (or 2<sup>nd</sup> dose) should be given at 16 years old</li> </ul> </li> <li>13-18 year olds – 1<sup>st</sup> dose (if not previously vaccinated) of a 2 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The booster (or 2<sup>nd</sup> dose) should be given at 16 years old</li> </ul> </li> </ul>	2 dose series for adolescence
<b>Serogroup B Meningococcal (Men B) Vaccines</b>			
<b>Vaccine Name: Trumenba</b> <b>Manufactured by:</b> <b>Wyeth Pharmaceuticals</b>	B	<ul style="list-style-type: none"> <li>16-23 years old – 1<sup>st</sup> dose of a 3 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The 2<sup>nd</sup> dose should be given 2 months after the 1<sup>st</sup></li> <li>The 3<sup>rd</sup> dose should be given 6 months after the 1<sup>st</sup> (or 4 months after the 2<sup>nd</sup>)</li> </ul> </li> </ul>	3 dose series for adolescence
<b>Vaccine Name: Bexsero</b> <b>Manufactured by:</b> <b>GlaxoSmithKline</b>	B	<ul style="list-style-type: none"> <li>16-23 years old – 1<sup>st</sup> dose of a 2 dose series should be given at this age.                             <ul style="list-style-type: none"> <li>The 2<sup>nd</sup> dose should be given at least 1 month after the 1<sup>st</sup></li> </ul> </li> </ul>	2 dose series for adolescence

<sup>o</sup>**Vaccine Name and Manufacturer:** Once a person is on a certain series, they should not switch to a new series. Keep record of which series has been started.

<sup>\*</sup>**Serogroups Covered:** There are 5 main strains (also known as serogroups) of *Neisseria meningitidis*, the bacteria that causes meningococcal disease. These 5 serogroups are A, B, C, W, and Y. In the United States, serogroups B, C, and Y cause the most illness.<sup>1</sup> In Kansas, over 60% of cases are from Serogroups C, W, and Y.<sup>2</sup>

<sup>1</sup> <https://www.cdc.gov/meningococcal/about/causes-transmission.html>

<sup>2</sup> Data presented by Chelsea Raybern, MPH from KDHE

## Resources

<http://www.immunize.org/catg.d/p4210.pdf> - Meningococcal Q&A

<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf> - package insert for Menactra

<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf> - package insert for Menveo

<http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf> - MMWR - Meningococcal Immunization Practices (ACWY)

<http://www.cdc.gov/mmwr/pdf/wk/mm6441.pdf#page=11> – Men B information/recommendations (page 11 start)

<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf> - package insert for Trumenba

<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf> - package insert for Bexsero